Green (Sustainable) VENTOLIN - Pharmacokinetics (PK) Study in Healthy Participants
Condition: Asthma Interventions: Drug: Salbutamol HFA-152a; Drug: Salbutamol HFA-134a Sponsor: GlaxoSmithKline Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 30, 2023 Category: Research Source Type: clinical trials
Re-analysis of ventilator-free days (VFD) in acute respiratory distress syndrome (ARDS) studies
ConclusionOur analyses show that thet-test and Poisson model are not appropriate for bi-modal data (such as VFD) where there is a large number of zero events. The two-part hurdle model was the most promising approach. There is a need for future research to investigate other analysis techniques, such as two-part quantile regression and to determine the impact on sample size requirements for comparative effectiveness trials. (Source: Trials)
Source: Trials - March 13, 2023 Category: Research Source Type: clinical trials
PT027 Recommended by FDA Advisory Committee as New Rescue Treatment for Asthma
9 November 2022 -- The Food and Drug Administration’s (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) has voted 16 to 1 that the data support a favourable benefit risk assessment for the use of PT027 (albuterol/budesonide) for the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 9, 2022 Category: Pharmaceuticals Source Type: clinical trials
PT027, a Novel Fixed-Dose Combination of Albuterol and Budesonide Used as Rescue Medicine Significantly Reduced the Risk of a Severe Exacerbation Compared to Albuterol by 27% in Patients with Asthma
First time an albuterol/budesonide fixed-dose combination rescue medication has been shown to reduce severe exacerbations
MANDALA Phase III trial results published in the New England Journal of Medicine and presented at ATS 2022 International... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 15, 2022 Category: Pharmaceuticals Source Type: clinical trials
Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma
Condition: Asthma Interventions: Drug: ARS-1; Drug: Albuterol MDI; Drug: Placebo Sponsor: ARS Pharmaceuticals, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 6, 2022 Category: Research Source Type: clinical trials
